. Only in 8 pts we observed G 3-4 haematological toxicity, thrombocytopenia and neutropenia (7 G3, 1 G4).
introduction
Cancers of the biliary tract are rare. The large majority of these tumors are not resectable when diagnosed and patients with advanced disease face a dismal prognosis [1, 2] . The efficacy of conventional palliative systemic chemotherapy seems negligible and there is no agreement on the best chemotherapeutic regimen. Several chemotherapy regimens have been proposed in patients with advanced biliary cancers. However, the published series is small and often includes a heterogeneous population of patients with both pancreatic and hepatocellular cancers as well as those with biliary cancers [3, 4] .
Hepatocellular carcinoma is one of the most common malignancies in the world. High mortality, linked to a delay in the diagnosis of cirrhosis and to the lack of symptoms, may represent a limit for the treatment options. Surgery is a valid therapeutic option potentially curative intent in selected patients, after a liver transplantation. Survival at 5 and 3 years is 30% and 85%, respectively [5, 6] . Systemic chemotherapy represents a palliative treatment after resective or transplant surgery and/or for inoperable patients after loco-regional failure. Moreover, HCC is a chemo-resistant disease because it expresses a high level of DPD, responsible for 5-FU resistance and over-expression of MDR1 gene, responsible for MDR [7, 8] .
In this paper, the role of Gemcitabine in biliary and hepatic carcinoma (either as a single agent or in combination) has been reviewed.
gemcitabine in biliary tract cancers
Gemcitabine is currently used for the treatment of advanced biliary tract cancer, also on the base of its shown activity in pancreatic adenocarcinoma, in advanced gallbladder and cholangiocarcinoma [9] [10] [11] .
The conventional Gemcitabine dose schedule is 1000 to 1200 mg/m 2 /day administered over 30 min on day 1, 8 and 15 followed by a week rest.
Several phase II studies have generated particular interest. The first trial, reported by Metzger et al. (Table 1) , describe the treatment of 13 patients with locally advanced or metastatic gallbladder or biliary cancer with Gemcitabine 1000 mg/m 2 for 7 or 8 weeks, then for 3 or of 4 weeks until disease progression. Only one case had partial response, 11 patients had stable disease and median time to progression was 7 months.
As shown in Table 1 , seven studies involving 167 assessable patients, the response rate was 8 to 60% with progression-free and overall survival from 3.4 to 7 months, and 6.3 and 16 months respectively [12] .
From Table 2 we can draw the following conclusions: Gemcitabine as a single agent shows a response rate between 20 and 30% with a median survival of 10 months.
symposium article
Gemcitabine has been candidate for trials in combination with other cytostatic agents (see Table 3 ).
As shown in Table 3 , in a total of seven studies with Gemcitabine-based combination chemotherapy and involving 167 assessable patients, the Response Rate was 9 to 53% with a progression-free survival between 4.1 and 5.8 and median overall survival of 11 months.
Conclusions
The best chemotherapeutic treatment for advanced biliary-tract cancer remains to be determined.
The single agent Gemcitabine represents an active and welltolerated therapy option. Gemcitabine may also be safely combined with other chemotherapeutic agents improving efficacy and survival. Future randomized studies are mandatory.
gemcitabine in hepatocellular carcinoma (HCC)
Systemic chemotherapy has been tested and shown to be minimally effective, or even ineffective, in HCC. Based on data from previous studies, Doxorubicine is generally considered to be the first-line treatment. This drug -used alone or in combination regimens -has shown a response rate between 20 to 30% with a median overall survival of approx. 4 months. Also combination chemotherapy has been studied extensively (see Tables 7-9 ) [13, 14] .
Recently, Gemcitabine has been investigated in advanced hepatocellular carcinoma as single agent or in combination. Phase II studies have evidenced a response rate between 17-18%; Gemcitabine administered in combination with Doxorubicin has shown a response rate of 24%. The Antracyclines often have serious side effects [15] [16] [17] . Availability of new drugs and in particular of Liposomal Doxorubicin (Caelyx Ò ) could be a good option of treatment and may lead to a reduction in the side effects. In phase I and II studies, the administration of Liposomial Doxorubicin on 21 patients has shown 1RP, 9SD and (47%) 11 PD with progression time >4.76 and median overall survival of 6.5 months [18] [19] [20] [21] [22] .
On the basis of the above data, we are conducting a phase II study on the treatment of HCC with combination of LD and Gemcitabine [23] .
patients and methods
From October 2003 to April 2005, we enrolled 21 patients (pts) with histological diagnosis of HCC or one lesion radiologically suggesting HCC with alpha-fetoprotein >400 and adequate haematological function. Characteristic of enrolled pts are shown in Table 5 . The patients were treated with Gemcitabine 1000 mg/m 2 diluted with 250 ml NS administered over 30 min on day 1 and 8 every 28 and Liposomal Doxorubicin (Caelyx Ò ) 30 mg/m 2 diluted with 250 ml 5% dextrose solution administered over 60 min on day 1 every 28. A total of 126 cycles were administered (median 6 per patient; range 1-11).
Tumor evaluation was performed every 3 months (3 cycles) during therapy.
Toxicity was evaluated at each cycle according to NCA CTC version 2.0. TTP from the first day until evidence of clinical progression or tumor progression assessed by CT scan measurement. OS was determined from the first day of treatment until the day of death.
RECIST criteria were applied to define radiological response to therapy.
All patients were valuable for toxicity and 20 for response. NCI CTC grade 3-4 toxicity and response are summarized in Table 6 .
conclusions
The combination of Gemcitabine and Liposomal Doxorubicin is safe and effective in the treatment of hepatocellular carcinoma. The patients' compliance was good and no life-threatening toxicity was experienced and disease control rate was approximately 65%. 
